Cantor Fitzgerald set a $36.00 price target on Abeona Therapeutics (NASDAQ:ABEO) in a report published on Tuesday, March 20th. The firm currently has a buy rating on the biopharmaceutical company’s stock.
Several other research analysts have also recently issued reports on the stock. Royal Bank of Canada restated a buy rating and issued a $26.00 target price on shares of Abeona Therapeutics in a report on Wednesday, January 24th. Maxim Group restated a buy rating and issued a $35.00 target price on shares of Abeona Therapeutics in a report on Wednesday, February 7th. HC Wainwright set a $30.00 target price on shares of Abeona Therapeutics and gave the company a buy rating in a report on Thursday, January 4th. Zacks Investment Research downgraded shares of Abeona Therapeutics from a buy rating to a hold rating in a research report on Thursday, November 23rd. Finally, BidaskClub downgraded shares of Abeona Therapeutics from a hold rating to a sell rating in a research report on Tuesday, January 23rd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company. The company has an average rating of Buy and a consensus target price of $28.88.
NASDAQ ABEO traded up $0.85 on Tuesday, hitting $19.00. 1,071,366 shares of the stock were exchanged, compared to its average volume of 1,101,810. Abeona Therapeutics has a fifty-two week low of $4.55 and a fifty-two week high of $22.75. The stock has a market capitalization of $838.28, a PE ratio of -28.79 and a beta of 1.29.
Abeona Therapeutics (NASDAQ:ABEO) last issued its earnings results on Friday, March 16th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.05). Abeona Therapeutics had a negative net margin of 3,263.92% and a negative return on equity of 24.57%. The company had revenue of $0.22 million during the quarter, compared to analyst estimates of $0.24 million. The business’s revenue for the quarter was down 16.0% on a year-over-year basis. sell-side analysts predict that Abeona Therapeutics will post -0.79 earnings per share for the current year.
Several large investors have recently bought and sold shares of ABEO. Teacher Retirement System of Texas acquired a new position in shares of Abeona Therapeutics during the 4th quarter worth $163,000. MetLife Investment Advisors LLC acquired a new position in shares of Abeona Therapeutics during the 4th quarter worth $194,000. SG Americas Securities LLC acquired a new position in shares of Abeona Therapeutics during the 4th quarter worth $218,000. Virtu Financial LLC acquired a new position in shares of Abeona Therapeutics during the 4th quarter worth $246,000. Finally, California State Teachers Retirement System acquired a new position in shares of Abeona Therapeutics during the 2nd quarter worth $275,000. 62.04% of the stock is currently owned by institutional investors and hedge funds.
WARNING: This piece was originally published by Macon Daily and is owned by of Macon Daily. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The correct version of this piece can be read at https://macondaily.com/2018/04/12/abeona-therapeutics-abeo-given-a-36-00-price-target-at-cantor-fitzgerald-updated-updated-updated.html.
About Abeona Therapeutics
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.